These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 29140739)

  • 1. CFTR Genotype and Maximal Exercise Capacity in Cystic Fibrosis: A Cross-sectional Study.
    Radtke T; Hebestreit H; Gallati S; Schneiderman JE; Braun J; Stevens D; Hulzebos EH; Takken T; Boas SR; Urquhart DS; Lands LC; Tejero S; Sovtic A; Dwyer T; Petrovic M; Harris RA; Karila C; Savi D; Usemann J; Mei-Zahav M; Hatziagorou E; Ratjen F; Kriemler S;
    Ann Am Thorac Soc; 2018 Feb; 15(2):209-216. PubMed ID: 29140739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between genotype and exercise tolerance in children with cystic fibrosis.
    Selvadurai HC; McKay KO; Blimkie CJ; Cooper PJ; Mellis CM; Van Asperen PP
    Am J Respir Crit Care Med; 2002 Mar; 165(6):762-5. PubMed ID: 11897641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
    Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
    Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations.
    Koch C; Cuppens H; Rainisio M; Madessani U; Harms H; Hodson M; Mastella G; Navarro J; Strandvik B; McKenzie S;
    Pediatr Pulmonol; 2001 Jan; 31(1):1-12. PubMed ID: 11180668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.
    De Boeck K; Weren M; Proesmans M; Kerem E
    Pediatrics; 2005 Apr; 115(4):e463-9. PubMed ID: 15772171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.
    McCague AF; Raraigh KS; Pellicore MJ; Davis-Marcisak EF; Evans TA; Han ST; Lu Z; Joynt AT; Sharma N; Castellani C; Collaco JM; Corey M; Lewis MH; Penland CM; Rommens JM; Stephenson AL; Sosnay PR; Cutting GR
    Am J Respir Crit Care Med; 2019 May; 199(9):1116-1126. PubMed ID: 30888834
    [No Abstract]   [Full Text] [Related]  

  • 9. Lack of effect of delta F508 mutation on aerobic capacity in patients with cystic fibrosis.
    Kaplan TA; Moccia-Loos G; Rabin M; McKey RM
    Clin J Sport Med; 1996 Oct; 6(4):226-31. PubMed ID: 8894334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-phenotype correlation for pulmonary function in cystic fibrosis.
    de Gracia J; Mata F; Alvarez A; Casals T; Gatner S; Vendrell M; de la Rosa D; Guarner L; Hermosilla E
    Thorax; 2005 Jul; 60(7):558-63. PubMed ID: 15994263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.
    Parad RB; Gerard CJ; Zurakowski D; Nichols DP; Pier GB
    Infect Immun; 1999 Sep; 67(9):4744-50. PubMed ID: 10456926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles.
    Terlizzi V; Castaldo G; Salvatore D; Lucarelli M; Raia V; Angioni A; Carnovale V; Cirilli N; Casciaro R; Colombo C; Di Lullo AM; Elce A; Iacotucci P; Comegna M; Scorza M; Lucidi V; Perfetti A; Cimino R; Quattrucci S; Seia M; Sofia VM; Zarrilli F; Amato F
    J Med Genet; 2017 Apr; 54(4):224-235. PubMed ID: 27738188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between genotype and pulmonary phenotype in cystic fibrosis patients with severe mutations.
    Geborek A; Hjelte L
    J Cyst Fibros; 2011 May; 10(3):187-92. PubMed ID: 21354377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis.
    De Boeck K; Zolin A; Cuppens H; Olesen HV; Viviani L
    J Cyst Fibros; 2014 Jul; 13(4):403-9. PubMed ID: 24440181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment.
    Edgeworth D; Keating D; Ellis M; Button B; Williams E; Clark D; Tierney A; Heritier S; Kotsimbos T; Wilson J
    Clin Sci (Lond); 2017 Aug; 131(15):2037-2045. PubMed ID: 28611235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic Fibrosis Gene Mutation Frequency Among a Group of Suspected Children in King Hussein Medical Center.
    Al-Abadi B; Al-Hiary M; Khasawneh R; Al-Momani A; Bani-Salameh A; Al-Saeidat S; Al-Khlaifat A; Aboalsondos O
    Med Arch; 2019 Apr; 73(2):118-120. PubMed ID: 31391700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
    Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype-phenotype relationships in a cohort of adult cystic fibrosis patients.
    Hubert D; Bienvenu T; Desmazes-Dufeu N; Fajac I; Lacronique J; Matran R; Kaplan JC; Dusser DJ
    Eur Respir J; 1996 Nov; 9(11):2207-14. PubMed ID: 8947061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.